OpenBiome vs Idexx Laboratories

Side-by-side comparison of AI visibility scores, market position, and capabilities

Idexx Laboratories leads in AI visibility (94 vs 42)
OpenBiome logo

OpenBiome

EmergingHealthcare

General

Cambridge MA YC W20 nonprofit FMT distributor that served 1,000+ hospitals for C. diff treatment; suspended distribution Dec 2024 after FDA enforcement discretion ended; submitted IND Phase 2 Nov 2024 — microbiome therapeutics regulatory transition.

AI VisibilityBeta
Overall Score
C42
Category Rank
#856 of 1158
AI Consensus
66%
Trend
up
Per Platform
ChatGPT
49
Perplexity
45
Gemini
35

About

OpenBiome is a Cambridge, Massachusetts-based nonprofit health research organization — backed by Y Combinator (W20) — that operated as the largest distributor of fecal microbiota transplant (FMT) products in the United States for over a decade, providing investigational FMT therapy to thousands of patients with recurrent Clostridioides difficile (C. diff) infection while accelerating research on human microbiome therapeutics. Founded in 2012, OpenBiome suspended FMT distribution as of December 31, 2024, following FDA regulatory changes that ended enforcement discretion for investigational FMT, and submitted an IND Phase 2 protocol application in November 2024 to pursue the FDA-approved clinical pathway for continued microbiome therapeutic development.

Full profile
Idexx Laboratories logo

Idexx Laboratories

LeaderHealthcare Tech

Enterprise

Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.

AI VisibilityBeta
Overall Score
A94
Category Rank
#19 of 290
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
92
Gemini
88

About

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.

Full profile

AI Visibility Head-to-Head

42
Overall Score
94
#856
Category Rank
#19
66
AI Consensus
71
up
Trend
stable
49
ChatGPT
99
45
Perplexity
92
35
Gemini
88
46
Claude
94
39
Grok
99

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.